NervGen Pharma Corp Announces Stock Options Grant

NervGen Pharma Corp, a clinical-stage biotechnology company based in Vancouver, Canada, has recently granted 600,000 incentive stock options to its directors and employees. The company, which specializes in developing neuroreparative therapeutics for conditions such as spinal cord injury, multiple sclerosis, Alzheimer’s disease, nerve damage, and neurodegenerative diseases, is listed on the TSX Venture Exchange.

The stock options are structured as follows:

  • 500,000 options granted to directors, exercisable at $4.00 per share for 5 years, with vesting occurring quarterly over 1 year.
  • 100,000 options granted to employees, exercisable at $4.00 per share for 10 years, with vesting occurring semi-annually over 4 years.

This move is part of NervGen Pharma’s strategy to incentivize its leadership and workforce, aligning their interests with the company’s growth and success.

Financial Overview and Recent Performance

As of May 13, 2025, NervGen Pharma’s close price was CAD 3.6, with a 52-week high of CAD 3.75 on May 5, 2025, and a 52-week low of CAD 1.65 on June 4, 2024. The company’s market capitalization stands at CAD 221,710,000. However, the price-to-earnings ratio remains negative at -10.05, reflecting the company’s current financial performance.

In its Q1 2025 financial results, NervGen Pharma reported a GAAP earnings per share (EPS) of -$0.06, indicating a loss. Despite this, the company remains focused on its operational goals and the development of its therapeutic pipeline.

Market Activity

On May 16, 2025, NervGen Pharma’s stock price reached a new 52-week high of CAD 4.54, marking a significant milestone for the company. This increase in stock price coincides with the announcement of the stock options grant, suggesting positive market sentiment towards the company’s future prospects.

NervGen Pharma continues to serve clients exclusively in Canada and maintains its commitment to advancing treatments for neurodegenerative diseases. For more information, the company can be accessed through its website at www.nervgen.com .